MOGADISHU, SOMALIA — The reported circulation of substandard and falsified branded pharmaceutical products in Somalia is raising growing concerns over patient safety, medicine quality, intellectual-property protection and the integrity of the country’s pharmaceutical supply chain.
Information obtained by Drug Eye Africa from pharmaceutical-sector and regulatory sources has raised concerns regarding products allegedly supplied through Taqwa Pharmaceutical & Surgical, a pharmaceutical trader based in Karachi, Pakistan, and associated with Mr. Naveed Qadir.
Sources within Somalia’s medicines regulatory authority have told Drug Eye Africa that Taqwa has been linked to the alleged falsification of more than 10 branded pharmaceutical products entering the Somali market.
According to the same sources, the National Medicines Regulatory Authority (NMRA) is aware of the matter and is currently working to take appropriate regulatory action in response to the reported violations.
More Than 10 Branded Products Reportedly Identified
According to regulatory sources who spoke to Drug Eye Africa, the concerns are not limited to a single medicine or manufacturer.
More than 10 branded pharmaceutical products have reportedly been identified in connection with suspected falsification involving Taqwa and the Somali market.
The reported scale of the issue has raised concerns that this may represent a broader pharmaceutical supply-chain problem rather than an isolated trademark or commercial dispute.
Duphaston and Navidoxine Among Products Raising Concerns
Among the products identified by sources are products presented as or resembling established brands including Duphaston and Navidoxine.
Concerns have been raised that products carrying or imitating established branding may have entered the Somali market despite questions regarding their actual manufacturing source, authorization and quality.
Where the identity or origin of a pharmaceutical product cannot be reliably established, the issue extends far beyond trademark infringement. Patients may potentially be exposed to medicines whose active ingredients, strength, formulation, manufacturing standards and overall quality cannot be assured.
Formal product authentication and, where appropriate, laboratory testing are therefore essential to establish whether individual products are falsified or substandard.
Hematone Brand Dispute
Another case brought to the attention of Drug Eye Africa concerns Hematone, a recognized Pakistani pharmaceutical brand associated with Indus Pharma and marketed in Somalia.
Sources familiar with the matter allege that Taqwa copied the Hematone brand and introduced an imitation product into the Somali market.
Sources associated with Indus Pharma have told Drug Eye Africa that the company has initiated legal proceedings against Taqwa concerning the alleged copying of its brand.
Drug Eye Africa is seeking documentary confirmation regarding the reported legal proceedings and their current status.
Somalia’s Medicines Regulator Working on the Case
Sources within Somalia’s medicines regulatory authority have confirmed to Drug Eye Africa that the authorities are aware of the reported activities and are working to address the matter.
The regulator’s involvement is particularly important because repeated falsification of established pharmaceutical brands could represent a significant threat to public health and confidence in Somalia’s medicine supply system.
Any final determination regarding individual products or companies should be based on regulatory investigation, documentation, product authentication, supply-chain tracing and laboratory analysis where required.
Potential Regional Implications
Industry sources have also raised concerns that questionable pharmaceutical products entering Somalia could move through informal distribution networks into neighbouring markets, including Kenya and Ethiopia.
Drug Eye Africa has not independently established evidence confirming cross-border smuggling involving the company, and these allegations require investigation by the competent authorities before conclusions can be reached.
Nevertheless, the possibility demonstrates the regional implications of pharmaceutical falsification. Medicines and pharmaceutical products routinely move across borders, making cooperation between national regulatory authorities, customs agencies and legitimate manufacturers essential.
More Than an Intellectual-Property Violation
The falsification of medicines should not be regarded simply as a dispute over brands or trademarks.
It is fundamentally a patient-safety and public-health issue.
When patients purchase a recognized pharmaceutical brand, they expect the medicine to originate from the legitimate manufacturer and to contain the correct active ingredient at the correct strength, manufactured according to established quality standards.
Deliberately imitating the identity or packaging of an established medicine can undermine that trust and potentially expose patients to serious risks.
It also damages legitimate pharmaceutical manufacturers and authorized distributors that have invested in product registration, quality assurance and compliant supply chains.
Stronger Enforcement and Market Surveillance Needed
The reported case highlights the need for stronger pharmaceutical market surveillance in Somalia.
Drug Eye Africa calls for suspected products to be traced through the supply chain, their batch numbers and packaging authenticated directly with legitimate manufacturers, and laboratory testing conducted where necessary.
Importers and distributors responsible for placing products on the market should also be traceable, while appropriate regulatory and legal measures should follow wherever deliberate falsification is established.
Greater cooperation between the Somalia National Medicines Regulatory Authority, customs authorities, pharmaceutical manufacturers, authorized distributors and regulatory authorities in exporting countries will be essential to prevent falsified medicines from reaching patients.
The reported identification of more than 10 suspected branded products also demonstrates the importance of moving beyond individual-product investigations toward examining the wider supply chain through which such products may have entered the country.
Drug Eye Africa will continue following this case and encourages manufacturers, distributors, healthcare professionals and members of the public who identify suspicious pharmaceutical products to report them to the appropriate regulatory authorities.
Drug Eye Africa will also provide Taqwa Pharmaceutical & Surgical, Mr. Naveed Qadir, Indus Pharma and other affected parties an opportunity to respond to the allegations and will update this report as additional verified regulatory, legal or laboratory evidence becomes available.
Editor’s Note: Allegations concerning named companies and individuals in this report are attributed to sources and should not be interpreted as final findings of wrongdoing unless confirmed through official regulatory decisions, court proceedings or independently verifiable evidence.
Drug Eye Africa — Protecting African Patients Through Pharmaceutical Quality, Transparency and Accountability
